Literature DB >> 35556190

The mutual relationship between the host immune system and radiotherapy: stimulating the action of immune cells by irradiation.

Tsubasa Watanabe1,2, Genki Edward Sato3, Michio Yoshimura3, Minoru Suzuki4, Takashi Mizowaki3.   

Abstract

The effects of irradiation on tumor tissue and the host immune system are interrelated. The antitumor effect of irradiation is attenuated in the immunocompromised hosts. In addition, radiation alone positively and negatively influences the host immune system. The positive effects of radiation are summarized by the ability to help induce and enhance tumor-antigen-specific immune responses. The cancer-immunity cycle is a multistep framework that illustrates how the tumor-antigen-specific immune responses are induced and how the induced antigen-specific immune cells exert their functions in tumor tissues. Irradiation affects each step of this cancer-immunity cycle, primarily in a positive manner. In contrast, radiation also has negative effects on the immune system. The first is that irradiation has the possibility to kill irradiated effector immune cells. The second is that irradiation upregulates immunosuppressive molecules in the tumor microenvironment, whereas the third is that irradiation to the tumor condenses immunosuppressor cells in the tumor microenvironment. When used in conjunction with radiotherapy, immune checkpoint inhibitors can further leverage the positive effects of radiation on the immune system and compensate for the negative effects of irradiation, which supports the rationale for the combination of radiotherapy and immune checkpoint inhibitors. In this review, we summarize the preclinical evidence for the reciprocal effects of radiation exposure and the immune system, and up-front topics of the combination therapy of immune checkpoint inhibitors and radiotherapy.
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Entities:  

Keywords:  Cancer-immunity cycle; Immune cells; Radiosensitivity; Radiotherapy

Year:  2022        PMID: 35556190     DOI: 10.1007/s10147-022-02172-2

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  79 in total

Review 1.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.

Authors:  Spencer C Wei; Colm R Duffy; James P Allison
Journal:  Cancer Discov       Date:  2018-08-16       Impact factor: 39.397

2.  Dendritic Cell Maturation Defines Immunological Responsiveness of Tumors to Radiation Therapy.

Authors:  Tiffany C Blair; Shelly Bambina; Alejandro F Alice; Gwen F Kramer; Terry R Medler; Jason R Baird; Miranda L Broz; Garth W Tormoen; Victoria Troesch; Marka R Crittenden; Michael J Gough
Journal:  J Immunol       Date:  2020-04-27       Impact factor: 5.422

3.  Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation.

Authors:  Anurag Gupta; Hans Christian Probst; Van Vuong; Alexandro Landshammer; Sabine Muth; Hideo Yagita; Reto Schwendener; Martin Pruschy; Alexander Knuth; Maries van den Broek
Journal:  J Immunol       Date:  2012-06-08       Impact factor: 5.422

Review 4.  Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.

Authors:  Golnaz Morad; Beth A Helmink; Padmanee Sharma; Jennifer A Wargo
Journal:  Cell       Date:  2021-10-07       Impact factor: 66.850

5.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

6.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment.

Authors:  Youjin Lee; Sogyong L Auh; Yugang Wang; Byron Burnette; Yang Wang; Yuru Meng; Michael Beckett; Rohit Sharma; Robert Chin; Tony Tu; Ralph R Weichselbaum; Yang-Xin Fu
Journal:  Blood       Date:  2009-04-06       Impact factor: 22.113

7.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

8.  Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.

Authors:  Corinne Faivre-Finn; David Vicente; Takayasu Kurata; David Planchard; Luis Paz-Ares; Johan F Vansteenkiste; David R Spigel; Marina C Garassino; Martin Reck; Suresh Senan; Jarushka Naidoo; Andreas Rimner; Yi-Long Wu; Jhanelle E Gray; Mustafa Özgüroğlu; Ki H Lee; Byoung C Cho; Terufumi Kato; Maike de Wit; Michael Newton; Lu Wang; Piruntha Thiyagarajah; Scott J Antonia
Journal:  J Thorac Oncol       Date:  2021-01-19       Impact factor: 15.609

9.  Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy.

Authors:  Paula D Bos; George Plitas; Dipayan Rudra; Sue Y Lee; Alexander Y Rudensky
Journal:  J Exp Med       Date:  2013-10-14       Impact factor: 14.307

10.  Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation.

Authors:  Jianzhou Chen; Yunhong Cao; Bostjan Markelc; Jakob Kaeppler; Jenny Af Vermeer; Ruth J Muschel
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.